Medical Dermatology
News
FDA approves first specific treatment for giant cell arteritis
The approval of tocilizumab was made with breakthrough therapy and priority review designations.
Conference Coverage
Topical JAK inhibitor showed promise in facial vitiligo
PORTLAND - The effects of a topical JAK inhibitor on facial vitiligo in four patients were promising.
Conference Coverage
Screen for comorbidities in pyoderma gangrenosum
PORTLAND, ORE. – A study of patients with pyoderma gangrenosum provides information about comorbidities to look out for in this population.
News from the FDA/CDC
Canagliflozin gets boxed warning for amputation
The risk of lower limb amputation associated with canagliflozin is now great enough to receive a boxed warning.
Conference Coverage
CC-220 shows efficacy, safety concerns in phase II SLE trial
The investigational agent CC-220 showed some efficacy but also important safety caveats in a 12-week, phase II trial.
Conference Coverage
Survey: Botulinum toxin achieves durable improvements in hyperhidrosis
SYDNEY, AUSTRALIA – Satisfaction with the effects of botulinum toxin therapy for axillary hyperhidrosis was high in a retrospective study of...